A method comparison of three immunoassays for detection of neutralizing antibodies against SARS‐CoV‐2 receptor‐binding domain in individuals with adenovirus type‐5‐vectored COVID‐19 vaccination. Issue 4 (23rd February 2022)
- Record Type:
- Journal Article
- Title:
- A method comparison of three immunoassays for detection of neutralizing antibodies against SARS‐CoV‐2 receptor‐binding domain in individuals with adenovirus type‐5‐vectored COVID‐19 vaccination. Issue 4 (23rd February 2022)
- Main Title:
- A method comparison of three immunoassays for detection of neutralizing antibodies against SARS‐CoV‐2 receptor‐binding domain in individuals with adenovirus type‐5‐vectored COVID‐19 vaccination
- Authors:
- Chen, Hui
Yu, Wanwan
Gao, Xiaojiao
Jiang, Weijun
Li, Xiaojun
Liu, Guorui
Yang, Yang - Abstract:
- Abstract: Objective: Detecting neutralizing antibodies targeting receptor‐binding domain (RBD) is important for the assessment of humoral protection and vaccine efficacy after vaccination. We compared the performance of three surrogate immunoassays for detection of neutralizing antibodies targeting RBD. Methods: We analyzed 115 serum samples obtained from individuals with Ad5‐vectored COVID‐19 vaccination using two competitive enzyme‐linked immunosorbent assays (Wantai BioPharm and Synthgene Medical Technology) and one competitive chemiluminescence assay (YHLO Biotech). Performance evaluation and methodology comparison were performed according to the Clinical and Laboratory Standards Institute related guidelines. Results: The precision met the manufacturers' statements. The linear range of the WANTAI was 0.0625–0.545 U/ml and the YHLO was 0.260–242.4 U/ml. The WANTAI's limit of blank (LoB) and limit of detection (LoD) were 0.03 and 0.06 U/ml, respectively. The YHLO's LoB and LoD were 0.048 and 0.211 U/ml, respectively. The correlations of semi‐quantitative results of Synthgene with quantitative results of YHLO (ρ = 0.566) and WANTAI (ρ = 0.512) were medium. For YHLO and WANTAI, there was a good agreement (0.62) and a strong correlation (ρ = 0.931). Passing–Bablok analysis and Bland‐Altman plot showed a positive bias (112.3%) of the YHLO compared to the WANTAI. The exclusion of samples >50 U/ml did not decrease bias. Conclusion: These findings contribute to a deeperAbstract: Objective: Detecting neutralizing antibodies targeting receptor‐binding domain (RBD) is important for the assessment of humoral protection and vaccine efficacy after vaccination. We compared the performance of three surrogate immunoassays for detection of neutralizing antibodies targeting RBD. Methods: We analyzed 115 serum samples obtained from individuals with Ad5‐vectored COVID‐19 vaccination using two competitive enzyme‐linked immunosorbent assays (Wantai BioPharm and Synthgene Medical Technology) and one competitive chemiluminescence assay (YHLO Biotech). Performance evaluation and methodology comparison were performed according to the Clinical and Laboratory Standards Institute related guidelines. Results: The precision met the manufacturers' statements. The linear range of the WANTAI was 0.0625–0.545 U/ml and the YHLO was 0.260–242.4 U/ml. The WANTAI's limit of blank (LoB) and limit of detection (LoD) were 0.03 and 0.06 U/ml, respectively. The YHLO's LoB and LoD were 0.048 and 0.211 U/ml, respectively. The correlations of semi‐quantitative results of Synthgene with quantitative results of YHLO (ρ = 0.566) and WANTAI (ρ = 0.512) were medium. For YHLO and WANTAI, there was a good agreement (0.62) and a strong correlation (ρ = 0.931). Passing–Bablok analysis and Bland‐Altman plot showed a positive bias (112.3%) of the YHLO compared to the WANTAI. The exclusion of samples >50 U/ml did not decrease bias. Conclusion: These findings contribute to a deeper understanding of surrogate viral neutralization assays and provide useful data for future comparison studies. Abstract : Graphic representation of correlation between the detection results of three assays. (A) The correlation of quantitative results of WANTAI ELISA with inhibition rate of Synthgene ELISA. (B) The correlation of quantitative results of YHLO CLIA with inhibition rate of Synthgene ELISA. (C) The correlation of quantitative results between WANTAI ELISA and YHLO CLIA. … (more)
- Is Part Of:
- Journal of clinical laboratory analysis. Volume 36:Issue 4(2022)
- Journal:
- Journal of clinical laboratory analysis
- Issue:
- Volume 36:Issue 4(2022)
- Issue Display:
- Volume 36, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 36
- Issue:
- 4
- Issue Sort Value:
- 2022-0036-0004-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-02-23
- Subjects:
- chemiluminescent immunoassay -- enzyme‐linked immunosorbent assay -- method comparison -- neutralizing antibodies -- SARS‐CoV‐2
Diagnosis, Laboratory -- Periodicals
Medical laboratory technology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/jcla.24306 ↗
- Languages:
- English
- ISSNs:
- 0887-8013
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.520000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21318.xml